Boehringer Ingelheim
Works in Cardiovascular · Dermatology · Genetic & rare · GI & liver · Hematology · Immunology · Infectious disease · Metabolic & endocrine · Musculoskeletal · Neurology · Oncology · Ophthalmology · Psychiatry · Renal & urogenital · Respiratory · Women's health
Boehringer Ingelheim is a clinical trial sponsor. It has 94 active clinical trials with 634,223 planned participants, across 16 therapeutic areas. Since 2021 it has completed 537 trials and stopped 93 early.
Trial track record · since 2021
Pipeline · 94 active trials
| Stage | Trial | Status |
|---|---|---|
On the market
29 approved drug applications with a product on the market.
Questions about Boehringer Ingelheim
Boehringer Ingelheim is lead sponsor of 94 active clinical trials on ClinicalTrials.gov, with 634,223 planned participants, in Cardiovascular, Dermatology, Genetic & rare, GI & liver and other areas. Since 2021 it has completed 537 trials and stopped 93 early.
From public sources only: ClinicalTrials.gov for trials, FDA's Data Dashboard, warning-letter listing and enforcement reports for the FDA record, and SEC filings for financials. Approve Suite is not affiliated with Boehringer Ingelheim; every record links to the source, and nothing here is advice.
See the rest of this profile
A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.
Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-10-16.
Approve Suite is not affiliated with Boehringer Ingelheim.
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.